What Bambusa Therapeutics does

Bambusa Therapeutics is a clinical-stage biotechnology company founded in 2024 and headquartered in Boston, Massachusetts, developing next-generation bispecific antibodies for immunological and inflammatory (I&I) diseases. The company is led by founder and CEO Shanshan Xu, M.D., Ph.D. (former Head of Global External Innovations at BioNTech who sourced the Biotheus acquisition that produced BNT327, partnered with BMS in a deal worth up to $11.1B), alongside CSO Thang Ho (ex-BioNTech, Takeda, CytomX, Vertex), CFO Todd James (ex-Acceleron/$11.5B Merck acquisition, Viridian), and VP of Corporate Development Melody Zhu (ex-Sanofi Dupixent team, BioNTech Shanghai).

Bambusa's core asset is a proprietary bispecific antibody engineering platform that combines advanced protein engineering with half-life extension technology (Fc modifications enhancing FcRn affinity, yielding ~29.4-day half-life for BBT002 and ~33-day for BBT001) and high-concentration subcutaneous delivery, producing 2+2 format IgG1 antibodies. The pipeline comprises four programs: BBT001 (IL-4Rα × IL-31 bispecific for atopic dermatitis, CSU, and prurigo nodularis in Phase 1), BBT002 (IL-4Rα × IL-5 bispecific for COPD, CRSwNP, and asthma in Phase 1b/2a), plus preclinical BBT003 (gastroenterology/IBD) and BBT004 (rheumatology/autoimmune). The lead programs target a $40B+ Type 2 dermatology market and an $80B+ Type 2 disorder market, with the broader immunology market projected to exceed $140B by 2032.

Bambusa is a pre-revenue, venture-backed private company that has raised approximately $105M+ across a $15M Series Seed (September 2024), ~$90M Series A led by RA Capital Management (February 2025), and an undisclosed oversubscribed Series A-2 (November 2025). The go-to-market is event-driven through scientific conference presentations (EAACI 2026, ATS 2026, AAD 2026) and PR-Newswire-issued press releases, with stated 2+2 strategic vision to advance BBT001 and BBT002 into pivotal studies by 2028. Future revenue, when generated, is expected to flow through biologics commercialization targeting specialist physicians, payers, and specialty pharmacies in immunology and inflammation.

Name

Bambusa Therapeutics

Legal name

Bambusa Therapeutics, Inc.

Website

https://bambusatx.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Bambusa Therapeutics is a clinical-stage Boston-based biotechnology company founded in 2024 that develops next-generation bispecific antibodies for immunological and inflammatory diseases, with two clinical-stage programs (BBT001 for atopic dermatitis and BBT002 for COPD/CRSwNP) and two preclinical programs targeting gastroenterology and rheumatology.

Ownership category

akta.pro rank

Product category

Immunology Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Fusion Proteins & Fc-Engineered Biologics (HLAAAAAD)

Keywords

• Bispecific antibodies
• Immunology therapeutics
• Inflammatory disease treatments
• Antibody engineering platform
• Clinical-stage biotechnology

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pre-revenue clinical-stage biotech: Bambusa is a clinical-stage biotechnology company with no commercially approved products as of the available sources. No products are currently generating revenue. Future revenue will be derived from commercialization of bispecific antibody biologics (BBT001, BBT002, BBT003, BBT004) currently in clinical or preclinical development. Funding to date has come from venture capital/private equity financing rounds.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Bambusa Therapeutics is a clinical-stage biotechnology company developing next-generation bispecific antibody therapeutics for immunological and inflammatory (I&I) diseases. The company leverages a proprietary antibody engineering platform combining half-life extension (Fc modifications enhancing FcRn affinity) with high-concentration subcutaneous delivery to create 2+2 format bispecific IgG1 antibodies that simultaneously engage two validated disease targets. Its pipeline includes BBT001 (IL-4Rα × IL-31) for Type 2 dermatology, BBT002 (IL-4Rα × IL-5) for Type 2 respiratory diseases, plus preclinical candidates BBT003 (IBD) and BBT004 (rheumatology/autoimmune).

Product overview

Bambusa Therapeutics is a clinical-stage biotechnology company offering a single integrated pipeline built on one underlying technology platform — its bispecific antibody engineering platform, which combines protein engineering with half-life extension and high-concentration subcutaneous delivery. The portfolio comprises four named drug programs: BBT001 (a bispecific IL-4Rα × IL-31 antibody for Type 2 dermatology, currently in Phase 1), BBT002 (a bispecific IL-4Rα × IL-5 antibody for Type 2 respiratory diseases such as COPD and CRSwNP, in Phase 1b/2a), and the preclinical programs BBT003 (gastroenterology/IBD) and BBT004 (rheumatology/autoimmune diseases). Together, these clinical and preclinical candidates form the company's "pipeline-in-a-program" approach to immunology and inflammation therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• BBT001: First-in-class, half-life-extended bispecific antibody targeting IL-4Rα and IL-31, in Phase 1 proof-of-concept development for atopic dermatitis (AD) and chronic spontaneous urticaria (CSU).
• BBT002
• BBT003
• BBT004

Products and services

• BBT001 First-in-class, half-life-extended bispecific IgG1 antibody using a 2+2 format that simultaneously engages IL-4Rα and IL-31 to address Type 2 inflammatory dermatological conditions including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. Currently in Phase 1 proof-of-concept development with demonstrated ~33-day half-life.
• BBT002 First-in-class, multi-targeting, half-life-extended bispecific antibody that simultaneously inhibits IL-4Rα and IL-5 signaling within a single molecule to block IL-4, IL-13, and IL-5 pathways. In Phase 1b/2a proof-of-concept development for Type 2 inflammatory respiratory diseases including COPD and CRSwNP, with ~29.4-day half-life supporting extended dosing intervals.
• BBT003 Preclinical bispecific antibody program focused on gastroenterology and inflammatory bowel disease (IBD), leveraging Bambusa's proprietary bispecific antibody engineering platform.
• BBT004 Preclinical bispecific antibody program focused on rheumatology and autoimmune diseases, leveraging Bambusa's proprietary bispecific antibody engineering platform.

Quantifiable outcome

• BBT002 demonstrated rapid, deep, and sustained eosinophil depletion, TARC reduction, and complete pSTAT6 inhibition for more than 8 weeks following multiple doses in Phase 1 MAD cohorts.
• +5 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Apogee Therapeutics: Clinical-stage biotech developing bispecific antibodies (e.g., APG777, APG990) for atopic dermatitis and other I&I indications with half-life extension technology. Closest direct competitor to Bambusa given shared bispecific platform strategy, target overlap (IL-13/IL-4Rα, OX40L), and similar clinical-stage milestones in dermatology and inflammation.

Emerging players

• Viridian Therapeutics: Clinical-stage biotech developing antibody therapeutics for autoimmune and inflammatory diseases (FcRn inhibitor veligrotug, lead candidate VRDN-003 for thyroid eye disease). Comparable stage, headcount, and antibody-engineering focus; Bambusa's CFO Todd James previously served as SVP at Viridian, indicating direct operational familiarity.
• Roivant Sciences: Holds multiple clinical-stage immunology Vants (e.g., Immunovant FcRn platform, Priovant) pursuing autoimmune and inflammatory indications with antibody-engineering platforms. Comparable operational model of advancing multiple clinical-stage I&I assets via focused subsidiary structures.

Broad incumbents

• Sanofi: Global biopharma with Dupixent (dupilumab) — the IL-4Rα anchor of Bambusa's lead programs — generating $13B+ in annual revenue across atopic dermatitis, asthma, CRSwNP, and other Type 2 indications. Most directly comparable incumbent competitor to Bambusa's BBT001/BBT002 mechanism and a likely strategic acquirer.
• Regeneron Pharmaceuticals: Co-developer of Dupixent (with Sanofi) and Libtayo, with a large antibody-engineering platform (VelociSuite). Comparable bispecific/antibody engineering expertise and overlapping immunology footprint, including IL-33 (itepekimab), positioning Regeneron as both a competitor and potential strategic partner.
• GSK: Owns the anti-IL-5 franchise (Nucala/mepolizumab, Cinqair/reslizumab) directly competing with BBT002's IL-5 arm in respiratory indications, and Tezspire (tezepelumab, anti-TSLP) in severe asthma. Comparable Type 2 inflammation pipeline depth and respiratory commercial footprint.
• AstraZeneca: Markets Fasenra (benralizumab, anti-IL-5R) and Tezspire (with Amgen) in severe asthma/eosinophilic disease, directly overlapping BBT002's IL-4Rα + IL-5 strategy in COPD, CRSwNP, and asthma. Comparable respiratory I&I commercial scale and pipeline depth.
• Eli Lilly: Markets Ebglyss (lebrikizumab, anti-IL-13) and Taltz (ixekizumab) in atopic dermatitis/psoriasis, directly competing with BBT001's Type 2 dermatology positioning. Comparable antibody-engineering capabilities (via Loxo/Dice) and immunology commercial scale.
• AbbVie: Markets Rinvoq (upadacitinib) and Skyrizi (risankizumab) in atopic dermatitis and IBD, and has pursued bispecific/dual-mechanism approaches (e.g., lutikizumab anti-IL-1α/β). Comparable broad immunology franchise and active interest in bispecific inflammation therapeutics.

Others

• BioNTech: Founder Shanshan Xu and CSO Thang Ho both previously led external innovation and clinical pharmacology at BioNTech. BioNTech's I&I portfolio (including BNT327 sourced via Biotheus acquisition, partnered with BMS for up to $11.1B) is thematically adjacent — and the original asset source — for Bambusa's pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bambusatherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bambusa Therapeutics